Daphne Karydas, director at Mineralys, sells $75,000 in MLYS stock

Director Daphne Karydas sold 3,000 MLYS shares at $25 ($75,000) on 31-Mar-2026 and exercised 3,000 options at $12.02 ($36,060), leaving her with 6,200 shares under a 10b5-1 plan. Mineralys reported Q4 2025 EPS of -$0.40 versus a -$0.94 forecast and the stock trades at $26.97 (≈+92.6% 1yr); analysts moved targets to $51 (BofA, Buy) and $52 (Stifel, Buy) while Jefferies cut to $30 (Hold). FDA accepted the NDA for lorundrostat and the company is preparing for commercial launch, but investors showed concern over rising G&A costs.

Analysis

Commercial-readiness for a first-in-class/specialty asset (clinical-to-commercial transition) shifts the primary business risk from pure clinical binary to executional: manufacturing scale-up, third-party specialty distribution, payer contracting and field sales hires. Those downstream needs inflate G&A and capex transiently while creating a multi-quarter cash burn cliff if launch timing slips or label/payer access is narrower than the market assumes. Winners in that path are not only the drug originator but the CDMOs, specialty pharmacies and commercialization vendors that secure early contracts; losers are small-cap peers with later-stage assets that will compete for the same limited channel capacity and payer attention.

Key catalysts in the next 3–18 months that will reprice the equity are: final labeling and any post-acceptance FDA communications, CMS/payer reimbursement guidance for the indicated population, commercial supply validation batches/inspection outcomes, and early script uptake metrics post-launch (TRx in the first 3 months). Tail risks include manufacturing failures, a restrictive label or slow payer access; any of these would justify a >40–60% downside re-rating given current implied expectations and limited near-term revenue visibility. Conversely, clean inspections plus favorable coverage decisions could compress time-to-revenue and push upside faster than current models assume.

The consensus appears to be pricing in smooth commercialization execution and broad payer access; that’s the fragility. Insider activity executed under a preset plan diminishes signalling value — use operational readouts (supply lots released, CMS/major PBM decisions, field hiring cadence) as gating items for convex option exposure rather than owning the equity outright into those binary operational events.

Key Decisions for Investors

• Tactical long-call spread on MLYS to capture commercialization upside while capping capital at risk: buy Jan 2027 30 calls and sell Jan 2027 50 calls, size 2–4% of biotech allocation. Rationale: 9–12 month tenor covers launch/coverage milestones; max loss = premium paid, max gain kicks in above $50 (tail upside) giving ~4–6x upside if launch executes. Stop: cut to zero on a material manufacturing/payer setback or two consecutive quarters of missed commercialization guidance.
• Hedge-funded pair: go 1x long MLYS equity and fund with a 0.5x short position in XBI (or short a small-cap biotech basket) to neutralize sector beta while keeping idiosyncratic upside. Timeframe 6–12 months. Risk/reward: isolates execution risk; expect returns if MLYS out-executes peers on launch metrics; trim if XBI rebounds on macro-induced risk-on.
• Protective put spread for downside insurance ahead of near-term operational readouts: buy 6–9 month MLYS 20 put and sell 12 put (or closest strikes), cost = limited premium. Use if you or desk holds material equity into upcoming supply/coverage milestones; this limits drawdown to predefined band and preserves upside above the long put strike.
• Event-driven short idea: initiate a modest short in a cash-burn peer that lacks near-term commercialization catalysts but trades at similar multiple to MLYS, size 1–2% NAV, use proceeds to fund option buys. Timeframe 3–9 months. Rationale: rotation into perceived launch winners will rerate pure R&D stories lower if funding conditions tighten or interest rates move up; stop-loss at 30% adverse move.